Rotavirus infection
diseaseOn this page
Also known as Rotavirus caused disease or disorderRotavirus disease or disorderRotavirus infectious disease
Summary
Rotavirus infection (MONDO:0005194) is a disease and 40 clinical trials. Top therapeutic interventions include nitazoxanide, rotavirus, live attenuated, and rotavirus, live. A subtype of primary viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 40
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Rotavirus infection |
| Mondo ID | MONDO:0005194 |
| EFO | EFO:0002622 |
| MeSH | D012400 |
| SNOMED CT | 18624000 |
| UMLS | C0035869 |
| MedGen | 19835 |
| Anatomy (UBERON) | UBERON:0001007 |
| Is cancer (heuristic) | no |
Also known as: Rotavirus caused disease or disorder · Rotavirus disease or disorder · Rotavirus infectious disease
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Rotavirus infection
Related subtypes (31): plantar wart, monkeypox, smallpox, rubella, human papilloma virus infection, Arenaviridae infectious disease, Astroviridae infectious disease, Caliciviridae infectious disease, cowpox, Flaviviridae infectious disease, Hepadnaviridae infectious disease, Herpesviridae infectious disease, influenza, Mononegavirales infectious disease, Nidovirales infectious disease, phlebotomus fever, Picornaviridae infectious disease, polyomavirus infectious disease, Togaviridae infectious disease, viral encephalitis, viral hepatitis, viral pneumonia, viral exanthem, deltaretrovirus infections, Bunyaviridae infectious disease, viral sexually transmitted disease, lentivirus infection, viral myocarditis, viral pericarditis, adenoviridae infectious disease, aleutian mink disease, human
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
2 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Rotavirus, Live | Approved (phase 4) |
| Rotavirus, Live Attenuated | Approved (phase 4) |
| HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN | Phase 3 (in late-stage trials) |
| Poliovirus Vaccine Inactivated | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Maltodextrin.
Clinical trials & evidence
Clinical trials
Clinical trials: 40.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 14 |
| PHASE3 | 9 |
| PHASE2 | 6 |
| PHASE1 | 6 |
| PHASE4 | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01266850 | PHASE4 | COMPLETED | Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules |
| NCT02542462 | PHASE4 | COMPLETED | Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study |
| NCT02992197 | PHASE4 | COMPLETED | The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity |
| NCT00090233 | PHASE3 | COMPLETED | Rotavirus Efficacy and Safety Trial (REST)(V260-006) |
| NCT00092443 | PHASE3 | COMPLETED | Dose Confirmation Efficacy Study (V260-007) |
| NCT00092456 | PHASE3 | COMPLETED | Consistency Lots Vaccine Study (V260-009) |
| NCT00130832 | PHASE3 | COMPLETED | Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED) |
| NCT00302640 | PHASE2/PHASE3 | COMPLETED | Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children |
| NCT00443846 | PHASE3 | COMPLETED | RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016) |
| NCT03207750 | PHASE3 | COMPLETED | This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals’ Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK’s Licensed Lyophilized Vaccine |
| NCT03367559 | PHASE3 | UNKNOWN | Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® in Healthy Infants Aged Between 6-8 Weeks in Vietnam |
| NCT05032391 | PHASE3 | COMPLETED | Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization |
| NCT05037435 | PHASE3 | COMPLETED | Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years. |
| NCT05621655 | PHASE2 | ACTIVE_NOT_RECRUITING | Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers |
| NCT00346892 | PHASE2 | COMPLETED | To Evaluate 2 Doses of GSK Biologicals’ Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV |
| NCT00757926 | PHASE1/PHASE2 | WITHDRAWN | Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants |
| NCT00880698 | PHASE2 | COMPLETED | Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers |
| NCT01328925 | PHASE2 | COMPLETED | Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children |
| NCT03483116 | PHASE2 | COMPLETED | A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine |
| NCT06080906 | PHASE2 | UNKNOWN | Phase II Clinical Trial of the Inactivated Rotavirus Vaccine |
| NCT06962904 | PHASE1 | ACTIVE_NOT_RECRUITING | CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults |
| NCT00280111 | PHASE1 | COMPLETED | Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants |
| NCT00981669 | PHASE1 | COMPLETED | Rotavirus Vaccine Produced by Butantan Institute |
| NCT01764256 | PHASE1 | COMPLETED | A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine |
| NCT04626856 | PHASE1 | UNKNOWN | Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus Infection |
| NCT06485258 | PHASE1 | COMPLETED | CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults |
| NCT00484952 | Not specified | UNKNOWN | Surveillance of Hospitalizations Due to Rotavirus Infections Among Children From Israel |
| NCT00683982 | Not specified | COMPLETED | Use of Nitazoxanide and Probiotics in Acute Diarrhea Secondary to Rotavirus |
| NCT00895492 | Not specified | COMPLETED | Two-year Surveillance of Rotavirus Genotypes Causing Acute Diarrhea in Children Younger Than 5 Years Requiring Emergency Room (ER) and Hospital Admission in Chile |
| NCT00981877 | Not specified | COMPLETED | Probiotics in the Management of Acute Rotavirus Diarrhea in Bolivian Children |
| NCT01357174 | Not specified | TERMINATED | ROTATEQ™ Post-Marketing Surveillance in the Philippines |
| NCT01363726 | Not specified | UNKNOWN | Surveillance of Rotavirus Gastroenteritis in Children <5 Years |
| NCT01467037 | Not specified | COMPLETED | Vaccine Effectiveness of RV1 in a Naïve Population |
| NCT01511133 | Not specified | COMPLETED | Serological Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in Stools of Infants Following Administration of Rotarix™ |
| NCT02220439 | Not specified | COMPLETED | Does the Fecal Microbiome Influence Rotarix Immunogenicity |
| NCT02538211 | Not specified | COMPLETED | The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses |
| NCT02662543 | Not specified | UNKNOWN | The Epidemiology and Etiology of Acute Gastroenteritis Among Estonian Children After Introduction of Rotavirus Vaccines |
| NCT03313128 | Not specified | COMPLETED | SaniVac Trial - Sanitation and Oral Rotavirus Vaccine Performance |
| NCT03870061 | Not specified | COMPLETED | Evaluation of an Infant Immunization Encouragement Program in Nigeria |
| NCT05212935 | Not specified | UNKNOWN | A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy |